(PharmaNewsWire.Com, May 15, 2017 ) Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types: - Acute myeloid (or myelogenous) leukemia (AML) - Chronic myeloid (or myelogenous) leukemia (CML) - Acute lymphocytic (or lymphoblastic) leukemia (ALL) - CLL
Publisher's analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020. For more information about this report: http://www.reportsweb.com/global-chronic-lymphocytic-leukemia-market-2016-2020 Covered in this report The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography: - Americas - APAC - EMEA
Publisher's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors - F. Hoffman-La Roche - AbbVie - Teva Pharmaceuticals - Gilead Sciences - Novartis - Johnson & Johnson
Table of Contents: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Disease overview PART 06: Pipeline analysis PART 07: Market landscape PART 08: Market segmentation by ROA PART 09: Market segmentation by type of molecule PART 10: Geographical segmentation PART 11: Market drivers PART 12: Impact of drivers PART 13: Market challenges PART 14: Impact of drivers and challenges PART 15: Market trends PART 17: Appendix
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
